Medicinal drugs in the U.S. The aim was to examine the effects of switching brands. Reuters reports that Merck Sharp and Dohme (MSD), a foreign unit of Merck, recently won an injunction against India-based Aprica Pharmaceuticals, which had planned to begin manufacturing generic versions of two diabetes drugs originally developed by Merck. Not all generic drugs increased in price. Every drug that has been developed by the original company has patent protection, which lasts for a variable amount of time, depending on the molecule. Can you imagine the savings when generics amount to, say, 35% of the dollar share? In these 3-tier plans, all generic drugs were de facto “preferred.” Now, however, a number of insurers have split their all-generics tier into a bottom tier consisting of “preferred” generics, and a second tier consisting of “non-preferred” generics, paralleling the similar split that one typically finds with branded products.
This news, however, was mostly a boon